Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label multicenter study of B1962 injection in advanced malignant solid tumors
CTR20244112Phase 2Active
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of B1962 in Nonhematologic neoplasms, epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), triple-negative breast cancer (TNBC), sponsored by Tasly Biopharmaceuticals Co., Ltd.. Started Dec 2024; status: active.
02
Drugs
B1962
03
Conditions
Nonhematologic neoplasmsepithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20244112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244112.